Pressure Builds on Astrazeneca to Rethink Pfizer Deal

AstraZeneca's sixth-largest investor is urging the U.K. drug giant's board to reverse its rejection of a $120 billion takeover offer from Pfizer and engage in talks. Dana Cimilluca joins MoneyBeat.

Advertisement